{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:18Z","timestamp":1790050938682,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T00:00:00Z","timestamp":1489190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40268-017-0179-7","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T07:52:30Z","timestamp":1489218750000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Canagliflozin as an Initial Therapy in Drug-Na\u00efve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy"],"prefix":"10.1007","volume":"17","author":[{"given":"Eiji","family":"Kutoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruma","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,11]]},"reference":[{"issue":"4","key":"179_CR1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515\u201331.","journal-title":"Endocr Rev"},{"issue":"6","key":"179_CR2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.clinthera.2015.03.004","volume":"37","author":"K Whalen","year":"2015","unstructured":"Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37(6):1150\u201366.","journal-title":"Clin Ther"},{"issue":"1","key":"179_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"6 Suppl. 1","key":"179_CR4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","volume":"40","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab. 2014;40(6 Suppl. 1):S4\u201311.","journal-title":"Diabetes Metab."},{"issue":"5","key":"179_CR5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","volume":"8","author":"RV Oliva","year":"2014","unstructured":"Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330\u20139.","journal-title":"J Am Soc Hypertens."},{"key":"179_CR6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nyas.12852","volume":"1358","author":"N Rosenthal","year":"2015","unstructured":"Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28\u201343.","journal-title":"Ann N Y Acad Sci"},{"key":"179_CR7","doi-asserted-by":"crossref","unstructured":"Brunton S, Reid TS. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes. Hosp Pract (1995). 2014;42(3):96\u2013108.","DOI":"10.3810\/hp.2014.08.1122"},{"issue":"6","key":"179_CR8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1254\/fpj.146.332","volume":"146","author":"C Kuriyama","year":"2015","unstructured":"Kuriyama C, Ueta K, Arakawa K. Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (Canaglu\u00ae). Nihon Yakurigaku Zasshi. 2015;146(6):332\u201341.","journal-title":"Nihon Yakurigaku Zasshi."},{"issue":"7","key":"179_CR9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0035-1569454","volume":"66","author":"E Kutoh","year":"2016","unstructured":"Kutoh E, Wada A, Murayama T, Hirate M. Ipragliflozin as an initial therapy in drug na\u00efve subjects with type 2 diabetes. Drug Res (Stuttg). 2016;66(7):345\u201350.","journal-title":"Drug Res (Stuttg)."},{"issue":"6 Suppl. 1","key":"179_CR10","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verg\u00e8s B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40(6 Suppl. 1):S28\u201334.","journal-title":"Diabetes Metab."},{"issue":"3","key":"179_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management-of hyperglycaemia-in-type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429\u201342.","journal-title":"Diabetologia"},{"issue":"6","key":"179_CR12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/1060028015572653","volume":"49","author":"JD Goldman-Levine","year":"2015","unstructured":"Goldman-Levine JD. Combination therapy when metformin is not an option for type 2 diabetes. Ann Pharmacother. 2015;49(6):688\u201399.","journal-title":"Ann Pharmacother"},{"key":"179_CR13","doi-asserted-by":"crossref","unstructured":"Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212\u201328.","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"issue":"1","key":"179_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nut.2007.10.008","volume":"24","author":"Y Ma","year":"2008","unstructured":"Ma Y, Olendzki BC, Merriam PA, et al. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition. 2008;24(1):45\u201356.","journal-title":"Nutrition."},{"issue":"11","key":"179_CR15","first-page":"1985","volume":"47","author":"RR Little","year":"2001","unstructured":"Little RR, Rohlfing CL, Wiedmeyer HM, NGSP Steering Committee, et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem. 2001;47(11):1985\u201392.","journal-title":"Clin Chem"},{"issue":"7","key":"179_CR16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00125-004-1453-0","volume":"47","author":"K Miedema","year":"2004","unstructured":"Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia. 2004;47(7):1143\u20138.","journal-title":"Diabetologia"},{"issue":"7","key":"179_CR17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia"},{"issue":"1","key":"179_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3810\/pgm.2011.01.2244","volume":"123","author":"E Kutoh","year":"2011","unstructured":"Kutoh E. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone. Postgrad Med. 2011;123(1):45\u201352.","journal-title":"Postgrad Med"},{"issue":"3","key":"179_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-009-9174-2","volume":"35","author":"E Kutoh","year":"2009","unstructured":"Kutoh E, Fukushima T. Insulin-dependent actions of pioglitazone in newly diagnosed, drug na\u00efve patients with type 2 diabetes. Endocrine. 2009;35(3):333\u201340.","journal-title":"Endocrine"},{"issue":"3","key":"179_CR20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-012-9596-0","volume":"41","author":"E Kutoh","year":"2012","unstructured":"Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug na\u00efve type 2 diabetes: a randomized, control trial. Endocrine. 2012;41(3):435\u201341.","journal-title":"Endocrine"},{"issue":"4","key":"179_CR21","first-page":"287","volume":"6","author":"E Kutoh","year":"2014","unstructured":"Kutoh E, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes. J Clin Med Res. 2014;6(4):287\u201394.","journal-title":"J Clin Med Res."},{"issue":"7","key":"179_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0035-1569454","volume":"66","author":"E Kutoh","year":"2016","unstructured":"Kutoh E, Wada A, Murayama T, Hirate M. Ipragliflozin as an initial therapy in drug na\u00efve subjects with type 2 diabetes. Drug Res. 2016;66(7):345\u201350.","journal-title":"Drug Res."},{"issue":"5","key":"179_CR23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MNH.0b013e328363ffc8","volume":"22","author":"H Sakurai","year":"2013","unstructured":"Sakurai H. Urate transporters in the genomic era. Curr Opin Nephrol Hypertens. 2013;22(5):545\u201350.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"179_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/07435800.2012.745128","volume":"38","author":"E Kutoh","year":"2013","unstructured":"Kutoh E, Hori T. Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-na\u00efve patients with type 2 diabetes. Endocr Res. 2013;38(3):151\u20139.","journal-title":"Endocr Res"},{"issue":"22","key":"179_CR25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"179_CR26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS): a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217\u201323.","journal-title":"Am Heart J"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0179-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-017-0179-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0179-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T15:28:19Z","timestamp":1494516499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-017-0179-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1007\/s40268-017-0179-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,11]]}}}